Core Viewpoint - Pharmaceutical stocks are considered strong long-term investments due to their consistent demand and revenue stability regardless of economic conditions [1] Group 1: Abbott Laboratories - Abbott Laboratories operates in pharmaceuticals, medical devices, diagnostics, and nutrition, providing diversification that mitigates risks from any single business segment [2] - The company has shown remarkable historical performance, with a cumulative compound return of 7,803,730% from 1937 to December of the previous year [2] - Abbott is recognized as a Dividend King, having raised its dividend for over 50 consecutive years, indicating a strong commitment to shareholder returns [3] - The company has authorized a new stock repurchase program of up to 7billion,furtherdemonstratingconfidenceinitsfutureandcommitmenttorewardingshareholders[4]Group2:Pfizer−Pfizer′sstockiscurrentlyundervaluedat11timesforwardearningsestimates,makingitanattractiveinvestmentopportunity[5]−Thecompanyhasfacedchallengeswithdecliningcoronavirusvaccinesalesbutanticipatessignificantgrowthfromnewproductsandastrongfocusononcology,projectinganadditional20 billion in revenue by 2030 from non-coronavirus products [5] - The acquisition of Seagen is already contributing positively to Pfizer's revenue, with plans to launch at least eight blockbuster oncology medicines by 2030 [5] - Pfizer pays a dividend of 1.68persharewithayieldof5.614 billion in sales for two consecutive quarters, with significant contributions from major brands [7] - The immunotherapy drug Darzalex achieved 3 billion in sales in a single quarter, showcasing the strength of J&J's product portfolio [7] - Recent acquisitions have positively impacted medtech growth, and the company has 19 billion in free cash flow, reinforcing its status as a Dividend King and a solid choice for passive income and long-term growth [8]
Abbott(ABT) The Motley Fool·2024-10-18 09:10